RxDoctor Payments Data

David Overton, PA

Physician Assistant · Lacey, WANPI 1851307003

Payments from drug & device makers

$2,368in general payments, 2019–2025

Across 138 payments — averaging $17.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$341
  • Lilly USA, LLC$217
  • Upsher-smith Laboratories LLC$194
  • Biohaven Pharmaceutical Holding Company Ltd.$137
  • Collegium Pharmaceutical, Inc.$136
  • plus $277 from 6 others

What the payments were for

  • Food & beverage$2,368100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,368 in reported general payments places this provider in the 90th percentile of 2,741 physician assistant providers in Washington.

See all physician assistant providers in Washington

Medicare billing

Part B allowed, 2024
$185,754
Medicare patients
186
Services billed
1,739

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Levorphanol Tartrate24$82,222
Nurtec OdtRimegepant Sulfate33$56,548
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,054$37,640
Oxycodone Hcl1,111$21,935
OxycontinOxycodone Hcl37$21,877
Xtampza ErOxycodone Myristate32$21,219
QuliptaAtogepant22$20,755
UbrelvyUbrogepant15$20,648
LinzessLinaclotide28$17,602
Buprenorphine64$17,552
BelbucaBuprenorphine Hcl26$16,976
Aimovig AutoinjectorErenumab-Aooe18$13,028
Gabapentin604$11,023
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen248$10,131
Morphine Sulfate ErMorphine Sulfate331$9,259

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy, Linzess$1,065$59,00465 claims
PfizerNurtec Odt$46$56,54833 claims
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$136$38,19558 claims
Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate, Buprenorphine Hcl, Buprenorphine-Naloxone$21$33,050551 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,741 physician assistant providers in Washington.

Other physician assistant in Lacey

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →